Literature DB >> 33010295

miRNA signature in glioblastoma: Potential biomarkers and therapeutic targets.

Omidvar Rezaei1, Kasra Honarmand2, Saeedeh Nateghinia1, Mohammad Taheri3, Soudeh Ghafouri-Fard4.   

Abstract

MicroRNAs (miRNAs) are transcripts with sizes of about 22 nucleotides, which are produced through a multistep process in the nucleus and cytoplasm. These transcripts modulate the expression of their target genes through binding with certain target regions, particularly 3' suntranslated regions. They are involved in the pathogenesis of several kinds of cancers, such as glioblastoma. Several miRNAs, including miR-10b, miR-21, miR-17-92-cluster, and miR-93, have been up-regulated in glioblastoma cell lines and clinical samples. On the other hand, expression of miR-7, miR-29b, miR-32, miR-34, miR-181 family members, and a number of other miRNAs have been decreased in this type of cancer. In the current review, we explain the role of miRNAs in the pathogenesis of glioblastoma through providing a summary of studies that reported dysregulation of these epigenetic effectors in this kind of brain cancer.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Glioblastoma; miRNA

Mesh:

Substances:

Year:  2020        PMID: 33010295     DOI: 10.1016/j.yexmp.2020.104550

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  10 in total

1.  Machine learning and bioinformatics approaches for classification and clinical detection of bevacizumab responsive glioblastoma subtypes based on miRNA expression.

Authors:  Jian Shi
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

2.  The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas.

Authors:  Guénaëlle Levallet; Fatéméh Dubois; Arthur Leclerc; Edwige Petit; Lien Bekaert; Maxime Faisant; Christian Creveuil; Evelyne Emery; Gérard Zalcman; Emmanuèle Lechapt-Zalcman
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

3.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in High-Grade Gliomas.

Authors:  Jianing Wu; Abdulrahman Al-Zahrani; Ozal Beylerli; Rinat Sufianov; Rustam Talybov; Svetlana Meshcheryakova; Galina Sufianova; Ilgiz Gareev; Albert Sufianov
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

4.  Integrated Analysis of Mutations, miRNA and mRNA Expression in Glioblastoma.

Authors:  ShiChao Wang; HuanMin Zhou; RuiJian Zhang; YanRu Zhang
Journal:  Int J Gen Med       Date:  2021-11-16

Review 5.  Ferroptosis Involvement in Glioblastoma Treatment.

Authors:  Andrei-Otto Mitre; Alexandru Ioan Florian; Andrei Buruiana; Armand Boer; Ioana Moldovan; Olga Soritau; Stefan Ioan Florian; Sergiu Susman
Journal:  Medicina (Kaunas)       Date:  2022-02-20       Impact factor: 2.430

Review 6.  Roles of the Neuron-Restrictive Silencer Factor in the Pathophysiological Process of the Central Nervous System.

Authors:  Xin-Jin Su; Bei-Duo Shen; Kun Wang; Qing-Xin Song; Xue Yang; De-Sheng Wu; Hong-Xing Shen; Chao Zhu
Journal:  Front Cell Dev Biol       Date:  2022-03-01

7.  miR-133a-5p Inhibits Glioma Cell Proliferation by Regulating IGFBP3.

Authors:  Xinzhi Yang; Dong Chen; Jiliang Hu; Qingsuo Zhao; Xing Fu; Wen Lv
Journal:  J Oncol       Date:  2022-08-02       Impact factor: 4.501

8.  LncRNA GAS5 represses stemness and malignancy of gliomas via elevating the SPACA6-miR-125a/let-7e Axis.

Authors:  Shuang Wu; Kaixi Ren; Jing Zhao; Juan Li; Bo Jia; Xiuquan Wu; Yanan Dou; Xiaowei Fei; Yu Huan; Xin He; Tingting Wang; Weihao Lv; Li Wang; Yan'gang Wang; Junlong Zhao; Zhou Fei; Sanzhong Li
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

Review 9.  Glioblastoma and MiRNAs.

Authors:  Swalih P Ahmed; Javier S Castresana; Mehdi H Shahi
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

10.  Targeted delivery of small noncoding RNA for glioblastoma.

Authors:  Ji Young Yoo; Margaret Yeh; Balveen Kaur; Tae Jin Lee
Journal:  Cancer Lett       Date:  2020-11-08       Impact factor: 8.679

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.